Table 2 Genotype frequencies of study subjects
Genotype | CKD | non-CKD | Total |
|---|---|---|---|
| Â | (n = 546) | (n = 2,777) | (n = 3,323) |
IL1B T-31C (rs1143627) | Â | Â | Â |
T T | 163 (29.9%) | 791 (28.5%) | 954 (28.7%) |
C T | 266 (48.7%) | 1,355 (48.8%) | 1,621 (48.8%) |
C C | 117 (21.4%) | 631 (22.7%) | 748 (22.5%) |
IL2 T-330G (rs2069762) | Â | Â | Â |
T T | 244 (44.9%) | 1,225 (44.1%) | 1,469 (44.2%) |
T G | 241 (44.3%) | 1,239 (44.6%) | 1,480 (44.6%) |
G G | 59 (10.9%) | 312 (11.2%) | 371 (11.2%) |
IL4 T-33C (rs2070874) | Â | Â | Â |
T T | 259 (47.4%) | 1,193 (43.0%) | 1,452 (43.7%) |
T C | 241 (44.1%) | 1,226 (44.2%) | 1,467 (44.2%) |
C C | 46 (8.4%) | 357 (12.9%) | 403 (12.1%) |
IL6 C-572G (rs1800796) | Â | Â | Â |
C C | 312 (57.1%) | 1,600 (57.6%) | 1,912 (57.6%) |
G C | 208 (38.1%) | 977 (35.2%) | 1,185 (35.7%) |
G G | 26 (4.8%) | 199 (7.2%) | 225 (6.8%) |
IL8 T-251A (rs4073) | Â | Â | Â |
T T | 254 (46.5%) | 1,281 (46.5%) | 1,535 (46.5%) |
A T | 235 (43.0%) | 1,204 (43.7%) | 1,439 (43.6%) |
A A | 57 (10.4%) | 273 (9.9%) | 330 (10.0%) |
IL10 T-819C (rs1800871) | Â | Â | Â |
T T | 252 (46.2%) | 1,175 (42.5%) | 1,427 (43.1%) |
C T | 239 (43.8%) | 1,222 (44.2%) | 1,461 (44.1%) |
C C | 55 (10.1%) | 370 (13.4%) | 425 (12.8%) |
IL13 C-1111T (rs1800925) | Â | Â | Â |
C C | 370 (67.9%) | 1,847 (66.5%) | 2,217 (66.8%) |
T C | 158 (29.0%) | 840 (30.3%) | 998 (30.1%) |
T T | 17 (3.1%) | 89 (3.2%) | 106 (3.2%) |
TNFA C-857T (rs1799724) | Â | Â | Â |
C C | 373 (68.3%) | 1,788 (64.4%) | 2,161 (65.0%) |
C T | 155 (28.4%) | 887 (31.9%) | 1,042 (31.4%) |
T T | 18 (3.3%) | 102 (3.7%) | 120 (3.6%) |
TNFA T-1031C (rs1799964) | Â | Â | Â |
T T | 383 (70.2%) | 1,934 (69.6%) | 2,317 (69.7%) |
C T | 144 (26.4%) | 764 (27.5%) | 908 (27.3%) |
C C | 19 (3.5%) | 79 (2.8%) | 98 (2.9%) |
CD14 T-260C (rs2569190) | Â | Â | Â |
T T | 144 (26.4%) | 785 (28.3%) | 929 (28.0%) |
T C | 275 (50.4%) | 1,412 (50.9%) | 1,687 (50.8%) |
C C | 127 (23.3%) | 580 (20.9%) | 707 (21.3%) |